These parliamentary studies, though seemingly low-profile, carry significant implications for access to medicines. They highlight a critical issue: the Canadian government's approach to public investment in research and development (R&D) and biomanufacturing, which often prioritizes private enterprise over public health. This is evident in two key studies by Parliamentary Standing Committees.
The first study, led by the Standing Committee on Science and Research (SRSR), explores ways to enhance the commercialization of innovations from Canadian universities, effectively transferring publicly funded research to the private sector. While this aligns with Canada's economic focus on R&D, it raises concerns. Publicly funded research at public universities has been frequently handed to private interests, who then control access and pricing, potentially impacting access to life-saving medicines. This is a critical area where public and private interests diverge.
The second study, by the Standing Committee on Health (HESA), addresses 'Canada's Pharmaceutical Sovereignty.' The COVID-19 pandemic exposed Canada's vulnerability, with shortages of existing drugs and limited access to new vaccines. The country's reliance on other nations for both finished medicines and their ingredients became apparent. Despite increased public investment in domestic biomanufacturing, much of it went to private sector capacity-building, raising questions about control and sovereignty.
These studies underscore the need for a balanced approach. While public and private interests can align, there are areas where they diverge, especially in health-critical sectors. Canada must ensure that public investment in R&D and biomanufacturing prioritizes public benefits. The country's history with innovations like monoclonal antibody treatments and mRNA vaccines highlights the importance of this balance. However, the benefits often accrue to private interests, as seen with AbCellera's stock market success and the high cost of the COVID-19 treatment.
Furthermore, Canada's reliance on private industry for product development can lead to challenges. Essential Medicines, deemed crucial by the WHO, are often not sold in Canada due to insufficient profitability, impacting patient access. The development of new treatments and vaccines faces similar issues, with Canadian research breakthroughs struggling to reach the market. The story of the Ebola vaccine highlights how Canada should fill market gaps, not rely on industry.
The recent funding for Canadian innovations like Lassa Fever and Marburg virus vaccines has come from foreign governments, not Canada. This underscores the need for a shift in strategy. Canada should move from subsidizing an already lucrative industry to addressing domestic gaps, prioritizing health needs over industry desires. The Biologics Manufacturing Centre in Montreal, despite receiving substantial funding, has been idle, illustrating the failure of the current approach.
In conclusion, these parliamentary studies highlight the importance of balancing public and private interests in medicine. Canada must ensure that its investments in R&D and biomanufacturing are directed towards public health, addressing gaps and prioritizing patients over profits.
